blepharoconjunctivitis


Also found in: Dictionary, Thesaurus, Medical.

blepharoconjunctivitis

[¦blef·ə·rō·kən‚jəŋk·tə′vīd·əs]
(medicine)
Inflammation of the eyelids and the conjunctiva.
References in periodicals archive ?
Atopic blepharoconjunctivitis occurs when inflammatory disease activity at the eyelid margins traumatizes the ocular surface, aggravating keratitis and conjunctivitis.
Deficient mucin production is normally an acquired condition secondary to chronic blepharoconjunctivitis (GRAHN & STOREY, 2004).
The patient first sought medical attention 11 days after the contact and had a skin condition and bacterial conjunctivitis diagnosed, which were treated with an oral antibiotic; 14 days after contact, she was noted to have two small pustular lesions on her right eyelid and had blepharoconjunctivitis diagnosed.
Many of these conditions can be managed by optometrists, especially those with AS and IP qualifications, and can include more complex cases of blepharitis and blepharoconjunctivitis, limbal and peripheral corneal infiltrates and non-perforating abrasions and foreign bodies.
At the upcoming ARVO Annual Meeting, InSite researchers will present data from a prior Phase 3 clinical study in patients with blepharoconjunctivitis supporting DexaSite's efficacy and safety.
Logically, a bacterial blepharoconjunctivitis or conjunctivitis will develop as and when the levels of bacteria exceed the protective functions of the tear film and the capacity of the tear film drainage to remove bacteria from the ocular surface.
At the recent BIO CEO Investor conference in New York City, InSite Vision shared additional data from the 2008 Phase 3 trial of AzaSite Plus in blepharoconjunctivitis.
Ocular herpes simplex virus (HSV) infection may involve the anterior and posterior parts of the eye and results in various clinical disorders including blepharoconjunctivitis, scleritis, episcleritis, keratitis, anterior uveitis, and posterior uveitis.
The company completed its first Phase 3 clinical trial of ISV-502 (AzaSite Plus[TM]), a topical combination antibiotic/corticosteroid product for the treatment of blepharoconjunctivitis, or lid margin disease.
InSite Vision Incorporated (AMEX:ISV) today announced preliminary results from the company's Phase 3a clinical trial of ISV-502 (AzaSite Plus[TM]) a topical combination antibiotic/corticosteroid product for the treatment of blepharoconjunctivitis.
ISV-502 is targeted at meeting this unmet need by conveniently treating both the infection and inflammation associated with blepharoconjunctivitis with one easy-to-use product.